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Introduction. The time required to obtain Institutional Review Board (IRB) approval is a frequent subject of efforts to reduce unnecessary delays in initiating clinical trials.
This study was conducted by and for IRB directors to better understand factors affecting approval times as a first step in developing a quality improvement framework.
Methods. 807 IRB-approved clinical trials from 5 University of California campuses were analyzed to identify operational and clinical trial characteristics influencing IRB
approval times.
Results. High workloads, low staff ratios, limited training, and the number and types of ancillary reviews resulted in longer approval times. Biosafety reviews and the
need for billing coverage analysis were ancillary reviews that contributed to the longest delays. Federally funded and multisite clinical trials had shorter approval times.
Variability in between individual committees at each institution reviewing phase 3 multisite clinical trials also contributed to delays for some protocols. Accreditation
was not associated with shorter approval times.
Conclusions. Reducing unnecessary delays in obtaining IRB approval will require a quality improvement framework that considers operational and study characteristics
as well as the larger institutional regulatory environment.
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Introduction
Institutional Review Boards (IRBs) are undergoing a major paradigm
shift as key stakeholders voice concerns about the economic
and human costs of federally mandated regulatory oversight of
human subjects research. Since their inception, IRBs were assigned
a “gatekeeper” role, ensuring that human research adheres to
accepted ethical and regulatory practices. As the workload and the
complexity of academic IRBs increases to meet the research and
development pressures placed on university faculty, the ability
of individual IRBs to function efficiently has been more closely
scrutinized [1].
Two recent reports of IRB processes have explored how the variation
between institutional workflow and trial characteristics affected the
time required to receive approval. Drezner and Cobb [2] evaluated
2 IRB approval time surveys. The first study, involving 33 sites and
425 approved protocols, found that operational characteristics such as
the number of IRB committees per site, meetings per month, IRB
staffing levels as well as study patient populations (e.g., pediatric, other
vulnerable populations, oncology) influenced time to approval.
A follow-up survey—expanded to 43 sites, over 1400 protocols—
revealed that high volume and experienced staff were associated with
faster approval times.
A second group [3] examined administrative processes and timing
of approvals for 218 trials from a national cancer center and affiliates.
Contrary to expectations, the authors found IRB approval accounted
for <25% of the total start-up time. Moreover, their analysis revealed
that much of the additional time was related to ancillary approvals from
entities such as Radiation Safety Committees and Medicare Coverage
Analysis. Given these findings, it is important to acknowledge
that focusing solely on IRB performance, in isolation from these other
entities, might not reduce the time required to open clinical trials.
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In addition, despite currently being neglected from methodological
discussions, speed alone should not be the sole metric considered
when seeking to improve IRB performance; in some cases, protocols
require revision and delays could be entirely appropriate.
To obtain a new perspective on IRB processes and efficiency, the IRB
directors and the University of California, Biomedical Research,
Acceleration, Integration, and Development (UC BRAID) collaborated
on a project to define and assess keymetrics for IRB efficiency and set the
stage for quality improvement efforts within and across 5 California
campuses of University of California (UC). The IRB directors identified
the main operational and study characteristics to be analyzed based on
their collective experience. Each of the variables selected was then
operationally defined (including supporting examples) to ensure data
harmonization and interinstitutional comparability.
The goals are were to identify (1) operational and study characteristics
that affect administrative, committee, and total IRB approval times,
(2) compare data between the 5 UC campuses for “lessons learned” that
can identify practices associatedwith shorter approval times, and (3) begin
developing a high-level quality improvement assessment framework.
Materials and Methods
Study Design
This study examines the relationship between the operational
characteristics (the “institutional capacity”) of 5 UC IRB offices, the
attributes of clinical trials (“nature of the task”) involving Food and Drug
Administration (FDA)-regulated products and the time required to obtain
IRB approval (“outcome”). Operational characteristics included fre-
quency of IRB meetings, staffing ratios, volume of approvals, and type of
accreditation. To calibrate performance drivers across campuses, analysis
for this segment of the study was restricted to phase 3 multisite studies.
Study attributes included phase, funding source, authorship, and types
of ancillary reviews, among others. Approval times were operationally
defined as:
∙ The number of days between initial submission of a research
approval application to the IRB and the submission being sent to
Committee (Administrative Review),
∙ The number of days between initial IRB review and full Committee
approval (Committee Review),
∙ The number of days between initiation and full IRB approval (total
duration).
Eligible trials met all of the following three criteria: (1) they were designed
to evaluate the safety, tolerability, or efficacy of an FDA-regulated device
or drug; (2) they were received by an IRB on or after January 1, 2014;
and (3) they obtained full IRB approval on or before December 31,
2014. Table 1 presents a detailed list of all data elements used in this analysis.
Quality Control Process
Data management and quality control adhered to ISO 8000-110:2008
standards and followed CRISP-DM guidelines [4, 5]. Each UC IRB Director
receivedmonthly quality control reports on the number of cases submitted
that month, the number and type of potential data entry errors for review,
and corrected or verified for specific cases. As a result, data entry errors
were <0.01% exceeding ISO/ANSI 13606-3:2009 [6].
Statistical Analyses
Data Preparation and Analysis
Continuous data, such as approval times, were evaluated to determine
their distribution type and variance homogeneity to help in the selection of
the statistical measures. This included Tukey and Grubbs tests to identify
statistically significant “outliers” and “extreme” cases. Continuous data not
found to satisfy assumptions required for parametric analyses underwent
either Mann-Whitney U test (with continuity correction), when examining
interactions with a single dichotomous variable (e.g., commercially
sponsored or PI initiated), or Kruskal-Wallis analysis of variance (ANOVA)
when exploring multiple categories (e.g., study phase). Wilcoxon-signed
rank test was used when the interactions of interest involved 2 continuous
variables such as duration and number of ancillary reviews.
Consistent with current recommendations for conducting quality
improvement assessment, we report descriptive statistics using median,
standard deviation, upper and lower quartiles, and percent outliers
(Tables 2 and 3). The combination of upper and lower quartiles is used in
quality improvement to identify how “in control” a particular process
is as well as whether there might be subprocesses or special causes asso-
ciated with “outlier” and “extreme” cases identified by the Tukey and
Grubbs tests that require special attention and additional analysis [7, 8].
Table 1. Data collected for analysis
Outcomes
Days between first received and first
reviewed
Days between first reviewed and
approved
Days between first received and approved
IRB operational characteristics
Total number of clinical trials reviewed Number of committees AAHRPP accreditation
Total number of FTEs Frequency of committee meetings Proportion of FTE holding CIP certification
FTE to protocol ratio
Study characteristics
Study phase Federally funded Investigational device exemption Biosafety review required
Multisite Private foundation funded Oncology/hematology Conflict of Interest Review required
PI-authored Investigational drug Number of ancillary reviews required Scientific Review Committee
Commercial sponsored Investigational device Radiation safety review required Medicare Billing/Coverage Analysis
AAHRP, Association for the Accreditation of Human Research Protection Programs; CIP, certified IRB professional; FTE, full-time equivalent; IRB, Institutional
Review Board; PI, principal investigator.
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Results
Eight hundred seven protocols met criteria for inclusion into this study of
which 205were phase 3multisite studies. Results presented in this section
are restricted to variables with statistically significant results ≤0.01.
Operational Characteristics
Operational Characteristics and Administrative Review Times
Staff workload, as measured by the number of protocols per FTE
(p= 0.0047) negatively impacted administrative review time whereas
staff training, as measured by percent of certified IRB professional staff
(p= 0.0029) had a positive effect. Interestingly, therewas also suggestion
of a queuing effect where more frequent IRB Committee meetings was
associated with shorter administrative review times (p= 0.0249).
Operational Characteristics and Committee Review Times
Dramatic differences in median time to complete reviews between
individual committees were observed within each university. Of the
15 individual IRB committees contributing to this study, 3 accounted for
82% of all the committee review outliers though only represented 30% of
the studies included in the analysis (p= 0.019). The median committee
review time for these 3 committees was 57 days (interquartile= 34–71)
compared with 28.5 (interquartile= 14–55.5) for the other 12 commit-
tees. The only other operational characteristic affecting committee
review times was the frequency of meetings (p= 0.0466).
Operational Characteristics and Total Times for Approval
Operational characteristics affecting total approval times reflect those
of administrative and committee review times. Specifically, higher staff
workload was associated with longer total approval times (p= 0.0026)
while certified IRB professional-certified staff were associated with
shorter total approval times (p= 0.0006).
Study Characteristics
Study Characteristics and Administrative Review Times
The most striking influence on time required to complete adminis-
trative reviews was the number and type of ancillary reviews by other
Table 2. Descriptive statistics for three approval times (outcome in days) for 807 qualifying clinical trials for each of the 5 University of California medical campus Institutional
Review Boards (IRBs)
Study attributes Review phase n Median SD Lower quartile (Q1) Upper quartile (Q3) Percent outliers
Phase 1 Admin review 172 26.0 42.2 14.0 36.0 14.5
IRB review 36.0 68.7 21.5 68.0 9.9
Total time 75.5 78.4 46.5 110.0 8.7
Phase 2 Admin review 299 21.0 27.1 15.0 35.0 13.4
IRB review 35.0 57.2 19.0 66.0 7.4
Total time 66.0 61.4 42.0 104.0 6.4
Phase 3 Admin review 262 23.5 27.5 15.0 37.0 14.1
IRB review 42.0 52.8 18.0 71.0 7.3
Total time 71.0 61.1 45.0 113.0 6.5
Device Admin review 74 28.0 38.0 17.0 49.0 20.3
IRB review 29.0 51.4 9.0 74.0 4.1
Total time 73.5 63.4 40.0 111.0 6.8
Multisite Admin review** 559 24.0 30.3 16.0 38.0 16.1
IRB review** 33.0 53.1 15.0 57.0 5.7
Total time** 63.0 62.3 40.0 96.0 6.4
Investigator-initiated Admin review** 196 29.0 36.1 18.0 49.0 5.6
IRB review 30.5 53.0 15.5 64.0 1.0
Total time 74.5 67.1 41.5 107.5 1.0
Commercial sponsored Admin review** 563 22.0 31.4 14.0 34.0 13.0
IRB review** 42.0 56.7 20.0 71.0 7.8
Total time 71.0 63.1 45.0 108.0 6.7
Federally funded Admin review 135 25.0 32.1 15.0 42.0 6.7
IRB review 23.0 57.5 6.0 48.0 0.0
Total time** 60.0 68.8 34.0 83.0 0.7
Private foundation Admin review** 218 15.0 31.9 14.0 27.0 1.4
IRB review** 60.0 67.7 35.0 100.0 3.7
Total time** 84.0 73.1 57.0 123.0 2.3
Investigational drug Admin review** 679 22.0 31.5 15.0 36.0 13.5
IRB review 36.0 54.8 19.0 68.0 7.2
Total time 70.0 62.5 43.0 104.0 6.2
Investigational device, yes Admin review 89 27.0 34.6 16.0 44.0 16.9
IRB review 35.0 56.8 15.0 76.0 5.6
Total time 72.0 62.2 44.0 112.0 9.0
Hematology, oncology, yes Admin review* 336 21.0 38.4 14.0 36.0 16.1
IRB review 39.0 60.2 19.0 72.0 7.4




regulatory committees (p= 0.0063). In particular, Biosafety Review
(median= 28, SD= 34.6, interquartile= 15–49), Scientific Review
(median= 27, SD= 36.6, interquartile= 15–48), and Coverage Analy-
sis (median= 23.0, SD= 32.3, interquartile= 15–38) were most
notably associated with longer approval durations. Indeed, all phase 3
multisite administrative review outliers (100%) implicated Coverage
Analysis as a driver. In addition, investigator-initiated studies
(median= 29, SD= 36.1, interquartile= 18–49) and multisite studies
(median= 24, SD= 53.1, interquartile= 16–38) also required sig-
nificantly longer time for administrative review.
Conversely, private foundation funded (median= 15, SD= 31.9,
interquartile= 14–27) and commercially sponsored studies (med-
ian= 22, SD= 31.4, interquartile= 14–34) required significantly less
administrative review time, as did studies involving investigational
drugs (median= 22, SD= 38.4, interquartile= 15–36) or oncology
studies (median= 21, SD= 38.4, interquartile= 14–36).
Study Characteristics and Committee Review Times
The number, rather than the type of ancillary reviews, associated with
a given study proved to be the dominant influence on Committee
Review times (p= 0.0027). Funding source also affected the time
required by an IRB Committee to approve a new proposal, often in the
opposite direction from that found with administrative review times.
For instance, private foundation funded (median= 60, SD= 67.7,
interquartile= 36–100) and commercially funded studies (median=
42, SD= 56.7, interquartile= 20–71) required significantly longer
committee time. Yet, federally funded (median= 23, SD= 57.5, inter-
quartile= 6–48), PI initiated (median= 30.5, SD= 53.0, inter-
quartile= 15.5–64), and multisite studies (median= 33, SD= 53.1,
interquartile= 15–57) required less committee review time.
Study Characteristics and Total Times for Approval
Consistent with both administrative and committee review times, the
number and types of ancillary reviews significantly influenced total
review time or duration. Biosafety Review (median= 81, SD= 67,
interquartile= 48–119), Scientific Review (median= 77, SD= 65.8,
interquartile= 47–116), and Coverage Analysis (median= 73,
SD= 65.5, interquartile= 45–110) again feature prominently but total
number of reviews (p≤ 0.0001) dominated as a mediator of total time
required to receive IRB approval (Fig. 1).
Funding source also was related to total approval time, with federally
funded studies (median= 60, SD= 68.8, interquartile= 34–83)
approved significantly faster than privately funded studies (median= 84,
SD= 73.1, interquartile= 57–123). Finally, multisite studies (med-
ian=63, SD= 62.3, interquartile= 40–96) also required significantly less
time to receive IRB approval.
Discussion
The present study of over 800 clinical trials is one of the largest mul-
tisite efforts to understand variables that affect IRB performance
Table 3. Descriptive statistics related to regulatory aspects for three approval times (outcome in days) for 807 clinical trials for University of California Institutional Review
Boards (IRBs)
Study attributes Review phase n Median SD Lower quartile (Q1) Upper quartile (Q3) Percent outliers
Radiation safety Admin review 410 22.0 34.5 14.0 37.0 15.4
IRB review 40.0 64.0 19.0 71.0 8.3
Total time 75.0 68.2 45.0 116.0 6.3
Biosafety review Admin review* 118 28.0 34.6 15.0 49.0 22.9
IRB review 38.0 60.7 21.0 68.0 6.8
Total time* 81.5 67.0 48.0 119.0 7.6
Conflicts of interest Admin review 47 22.0 26.2 15.0 30.0 12.8
IRB review 57.0 54.6 21.0 90.0 8.5
Total time 85.0 56.2 50.0 118.0 10.6
Scientific review Admin review** 457 27.0 36.6 15.0 48.0 21.0
IRB review 36.0 58.1 19.0 68.0 7.7
Total time** 77.0 65.8 47.0 116.0 7.7
Coverage analysis Admin review** 691 23.0 32.3 15.0 38.0 15.5
IRB review 37.0 59.1 19.0 69.0 7.4
Total time* 73.0 65.5 45.0 110.0 7.2
* p≤ 0.01.
** p≤ 0.001.
Median 25%-75% Non-Outlier Range 
0 1 2 3 4 5

















Fig. 1. Association between number of ancillary reviews and overall time to
Institutional Review Board (IRB) approval. Account name: CITY DRAGON
CHINESE INC. Customer account no: 8030771326.
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adding to the emerging body of literature [2, 3, 9–13]. Uniquely, this
study was created by and for IRB directors from multiple campuses
working under the same institutional policies in meeting those insti-
tutional polices as efficiently as possible. This allowed us to not only
focus on issues identified as involved with the regulatory process but
also to compare procedures and begin formulating best practices. The
findings both support previous published results as well as identify new
factors affecting IRB approval time.
Consistent with previous findings [2, 3], ancillary reviews increased the
time required to receive IRB approval. Three campuses reported only
15% of their clinical trials required 3 or more ancillary reviews whereas
50% of the clinical trials at the other 2 campuses had 3 or more ancillary
reviews. The median time to receive IRB approval between the 2 groups
was 58 and 85 days, respectively. The difference between campuses was
true even for phase 3 multicenter studies, suggesting a difference in
policy interpretation at the 2 groups of campuses. This underscores the
importance of not simply writing policies but also providing clarifying
use cases to help calibrate decisions about when the IRB can review and
make recommendations that might otherwise be the responsibility of a
separate ancillary committee.
A new factor identified is the impact of workload (number of proto-
cols per FTE) on administrative review time. There was no attempt to
identify optimal ratios in the tradeoff between cost of IRB employees
and the opportunity costs of delayed IRB approval.
The study highlights the value of frequent feedback in improving per-
formance in 2 different domains: data quality and response time. Using
ISO/ANSI 13606-3:2009 standards to provide monthly feedback and
data entry errors reduced the rate of errors from 6% during the first
month to<0.01% by the ninth month. Equally striking was the reduction
in median total duration from 103 days during the first quarter of this
study to a median of 62 days by the third quarter of data collection.
There is enormous potential for improvement by including quality
improvement such as Statistical Process Control and Pareto Charts to
monitor both durations and factors associated with “outlier” rates.
At this time, and within this consortium, each of the campuses is
individually applying “lessons learned” to their internal operations
and the across-campus effort continues under the UC BRAID
leadership.
Finally, this study suggests that while there are categories of study
and operational characteristics that impact approval times, the pattern
of critical variables is likely to vary from one IRB to the next.
Rather than focus on a single outcome measure such as total duration
time, it is more productive to develop a quality improvement frame-
work that individual IRBs can use to identify challenges at their
respective campuses. Doing so would permit the development of a
common problems-common solutions matrix. Such a framework would
minimally be composed of 4 dimensions (see Table 4).
The first, most obvious and seldom mentioned in the literature, is IRB
staff workload. This domain has 4 major components:
(1) Staffing levels for the volume of work,
(2) the mix of trained analysts and support staff,
(3) the adequacy of infrastructure such as electronic tracking
systems, and
(4) the skills and training of the staff.
The second potential dimension for assessment is committee-to-
committee variation in workflow, expertise and guidance provided by
staff and the chairperson. For example, 3 of the 13 Committees
included in this study accounted for the majority of “outlier” cases
even though they reviewed only 30% of the protocols. Potential causes
include:
(1) Committee workload (the number of new, renewal, deferred,
addendum, violation, adverse event, and safety reports assigned to
each committee member per meeting);
(2) The knowledge and expertise of committee members relative to
the content of the IRB application (e.g., a committee member—
unfamiliar with standard of care for a given discipline—may not be
comfortable in determining risk levels and will ask for additional
information from an applicant); and
(3) The internal dynamics of a committee. There may be times in
which competition develops between committee members to
identify errors in the study design.
The third dimension is the quality of submitted protocols. Regulations
affecting IRB determinations are both dynamic and complex. Timing
and context matter: what may have been considered a complete and
adequate application 5 years ago might no longer meet regulatory
review requirements. Conversely, advances in complex adaptive
clinical trial designs or in personalized medicine research pose
challenges to current guidelines. Drivers of these issues are:
(1) Current regulatory knowledge of the investigator submitting a
protocol,
(2) The degree to which that investigator is able to articulate the risk
and benefits of the proposed protocol.
Table 4. Suggested analytic framework for Institutional Review Boards quality improvement efforts
Dimension Potential contributors Potential solutions






Identify key content knowledge and work ethics
Explore options for supportive technology
Committee workload Meeting frequency
Volume and types of reviews X meeting X committee member
Member training/understanding





Explore options for supportive technology
Application quality Researcher knowledge of current regulatory requirements Training/concierge service
Supportive templates and use cases
Regulatory environment Number of other regulatory units Institutional policy on sequential or parallel processing
Harmonized requirements and application forms
Supportive templates and use cases
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The last dimension is the regulatory environment within which the IRB
functions. This analysis corroborates previous studies [3] suggesting
that much of the delay in IRB approval processes is driven by ancillary
reviews from other regulatory units such as Medicare Coverage
Analysis or Radiation Safety. Examples of such issues include:
(1) Campus policies determining if ancillary reviews are conducted in
parallel or in sequence to IRB review,
(2) The degree of communication and harmonization between the
different regulatory units,
(3) The overall culture of the larger regulatory environment within
which the IRB functions.
The present study has a number of potential limitations. First there
was no attempt to define what quality of IRB administrative or
committee reviewmeans. The rapid risk-benefit analysis for a study does
not mean it is done well. This is an essential element of analysis that must
be considered in any future iteration. Second, it is possible that important
trial characteristics such as enrollment of vulnerable populations or
research involving Veterans Administration (VA) facilities have been
overlooked. Third, we did not attempt to control for the uneven
volumes of human subjects research activity across the 5 campuses.
These differences may operate to influence approval times in yet
unknown ways. The 807 clinical trials that met criteria for inclusion into
this study represented only a portion of the human subjects research
portfolio at the participating UC campuses. As such, review and approval
times may not reflect the levels of efficiencies for a given campus. Finally,
the time to approval analyzed in the present study did not include the
time from approval to the time of release nor enrollment of the first
patients into a trial, an important factor considered by many in industry
to be representative of an institution’s regulatory efficiency.
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